FI760884A - - Google Patents

Info

Publication number
FI760884A
FI760884A FI760884A FI760884A FI760884A FI 760884 A FI760884 A FI 760884A FI 760884 A FI760884 A FI 760884A FI 760884 A FI760884 A FI 760884A FI 760884 A FI760884 A FI 760884A
Authority
FI
Finland
Application number
FI760884A
Other languages
Finnish (fi)
Other versions
FI62087C (fi
FI62087B (fi
Inventor
Willem Jacob Van Der Burg
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI760884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI760884A publication Critical patent/FI760884A/fi
Application granted granted Critical
Publication of FI62087B publication Critical patent/FI62087B/fi
Publication of FI62087C publication Critical patent/FI62087C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
FI760884A 1975-04-05 1976-04-01 Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet FI62087C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL7504075 1975-04-05
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (3)

Publication Number Publication Date
FI760884A true FI760884A (es) 1976-10-06
FI62087B FI62087B (fi) 1982-07-30
FI62087C FI62087C (fi) 1982-11-10

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
FI760884A FI62087C (fi) 1975-04-05 1976-04-01 Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet

Country Status (17)

Country Link
US (1) US4062848A (es)
JP (1) JPS5942678B2 (es)
BE (1) BE840362A (es)
CA (1) CA1076571A (es)
CH (1) CH622261A5 (es)
DE (1) DE2614406A1 (es)
DK (1) DK142498B (es)
ES (2) ES446634A1 (es)
FI (1) FI62087C (es)
FR (1) FR2305986A1 (es)
GB (1) GB1543171A (es)
HU (1) HU179401B (es)
IE (1) IE42969B1 (es)
LU (1) LU74680A1 (es)
NL (2) NL189199C (es)
SE (1) SE422941B (es)
ZA (1) ZA761756B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
JPH055746Y2 (es) * 1988-04-27 1993-02-15
PT95522B (pt) * 1989-10-05 1997-08-29 Sankyo Co Processo para a preparacao de novos compostos tetraciclicos com accao anti-alergica e anti-asmatica e de composicoes farmaceuticas que os contem
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ATE254918T1 (de) * 1998-04-02 2003-12-15 Akzo Nobel Nv Orale flüssige lösung enthaltend das antidepressivum mirtazapine
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
IL146024A0 (en) 1999-04-19 2002-07-25 Teva Pharma Novel synthesis of piperazine ring
KR20020019902A (ko) * 1999-04-19 2002-03-13 추후보정 피페라진 고리 함유 화합물의 신규한 합성법 및 결정화법
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) * 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
WO2001038329A1 (fr) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
WO2001042239A1 (fr) 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Procede de preparation d'un compose pyridinemethanol
EP1251854A2 (en) * 2000-01-19 2002-10-30 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
CZ302368B6 (cs) 2000-02-11 2011-04-13 N.V. Organon Farmaceutický prostredek
IN190478B (es) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002070513A1 (en) 2001-03-01 2002-09-12 Teva Pharmaceutical Industries Ltd. Methods for the preparation of mirtazapine intermediates
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
WO2006022182A1 (ja) * 2004-08-24 2006-03-02 Sumitomo Chemical Company, Limited ２－（４－メチル－２－フェニルピペラジン－１－イル）－３－シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
EP1904843A2 (en) 2005-07-08 2008-04-02 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
CN101304988A (zh) * 2005-11-14 2008-11-12 住友化学株式会社 制备2-(4-甲基-2-苯基哌嗪-1-基)吡啶-3-甲醇的方法
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
MX2008011434A (es) * 2006-03-06 2008-11-18 Organon Nv Metodo mejorado para retirar del tratamiento hormonal los sintomas vasomotores inducidos por eliminación de hormonas.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
MX2009010967A (es) 2007-04-11 2009-12-15 Organon Nv Un metodo para la preparacion de mirtazapina.
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
AR066004A1 (es) * 2007-04-11 2009-07-15 Organon Nv Un metodo para la preparacion de una benzazepina enantiomericamente pura
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
WO2010046851A1 (en) 2008-10-22 2010-04-29 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (es) * 1966-03-12
NL7202963A (es) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
DE2614406A1 (de) 1976-10-14
ES459348A1 (es) 1978-03-16
FI62087C (fi) 1982-11-10
AU1236176A (en) 1977-09-29
ES446634A1 (es) 1977-11-01
GB1543171A (en) 1979-03-28
IE42969L (en) 1976-10-05
FI62087B (fi) 1982-07-30
CH622261A5 (es) 1981-03-31
IE42969B1 (en) 1980-11-19
HU179401B (en) 1982-10-28
DE2614406C2 (es) 1992-02-20
SE7603931L (sv) 1976-10-06
NL7504075A (nl) 1976-10-07
NL940007I1 (nl) 1994-06-01
JPS51122099A (en) 1976-10-25
DK142498C (es) 1981-07-06
DK142676A (es) 1976-10-06
SE422941B (sv) 1982-04-05
DK142498B (da) 1980-11-10
LU74680A1 (es) 1976-11-11
NL940007I2 (nl) 1994-10-17
NL189199B (nl) 1992-09-01
NL189199C (nl) 1993-02-01
FR2305986B1 (es) 1980-06-13
JPS5942678B2 (ja) 1984-10-16
ZA761756B (en) 1977-03-30
FR2305986A1 (fr) 1976-10-29
US4062848A (en) 1977-12-13
BE840362A (fr) 1976-10-04
CA1076571A (en) 1980-04-29

Similar Documents

Publication Publication Date Title
DK142498C (es)
FR2330453B1 (es)
DK141788C (es)
FR2315491B1 (es)
JPS5437913B2 (es)
JPS5439157Y2 (es)
JPS51147877U (es)
JPS5247064U (es)
JPS533734Y2 (es)
AU495836B2 (es)
JPS5221984Y2 (es)
JPS557011Y2 (es)
JPS5332895Y2 (es)
JPS51146925U (es)
JPS5281672U (es)
JPS51163025U (es)
JPS51144659U (es)
JPS5256760U (es)
JPS51118786U (es)
JPS51162259U (es)
JPS5241180U (es)
JPS5230634U (es)
BG22469A1 (es)
BG23288A1 (es)
CH304475A4 (es)

Legal Events

Date Code Title Description
MA Patent expired
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L60

Extension date: 20010401

MA Patent expired

Owner name: AKZO N.V.